Acting on Actionable Mutations in Metastatic Prostate Cancer

Area of Science:

• Oncology
• Genetics
• Medical Therapeutics

Background:

• Metastatic castration-resistant prostate cancer (mCRPC) affects numerous men, with a quarter exhibiting homologous recombination repair (HRR) pathway genomic alterations.
• Poly (ADP-ribose) polymerase (PARP) inhibitors represent a targeted therapeutic option for patients with specific genomic alterations.
• Integrating genomic data and treatment sequencing in prostate cancer management presents ongoing challenges.

Approach:

• This content reviews the clinical context of genomic alterations in mCRPC.
• It discusses diagnostic and management challenges associated with HRR pathway alterations.
• The review synthesizes relevant literature on PARP inhibitor efficacy and sequencing strategies.

Key Points:

• Men with BRCA2 alterations appear to gain the most benefit from PARP inhibitors.
• Incorporating genomic information into treatment decisions for prostate cancer is complex.
• Early combination therapy with PARP inhibitors has not yet demonstrated an overall survival benefit.

Conclusions:

• Genomic profiling is crucial for identifying patients who may benefit from PARP inhibitors in mCRPC.
• While overall survival benefits are pending, early PARP inhibitor use may offer advantages for select patients, particularly those with BRCA2 alterations.
• Further research is needed to optimize treatment sequencing and combination strategies involving PARP inhibitors in prostate cancer.